What is Scilex Holding Company (SCLX) Stock Return on Shareholders’ Capital?

With 0.59 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.03 million shares. During the session, the Drug Manufacturers – General company that operates in wider Healthcare sector, reached to the highest price of $0.8275 whereas the lowest price it dropped to was $0.7712. The 52-week range on SCLX shows that it touched its highest point at $8.37 and its lowest point at $0.73 during that stretch. It currently has a 1-year price target of $6.25. Beta for the stock currently stands at 0.90.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SCLX was down-trending over the past week, with a drop of -12.79%, but this was down by -37.50% over a month. Three-month performance dropped to -49.04% while six-month performance fell -37.98%. The stock lost -85.21% in the past year, while it has lost -60.78% so far this year. A look at the trailing 12-month EPS for SCLX yields -0.89 with Next year EPS estimates of -0.41. For the next quarter, that number is -0.17. This implies an EPS growth rate of 49.61% for this year and 37.21% for next year.

Float and Shares Shorts:

At present, 166.19 million SCLX shares are outstanding with a float of 102.88 million shares on hand for trading. On 2024-04-30, short shares totaled 8.62 million, which was 711.00004 higher than short shares on 1711584000. In addition to Dr. Henry H. Ji Ph.D. as the firm’s Executive Chairman, Mr. Jaisim Shah serves as its President, CEO & Director.

Institutional Ownership:

Through their ownership of 0.14685 of SCLX’s outstanding shares, institutional investors have minority control over the company.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2023-12-31, SCLX reported revenue of $13462000.0 and operating income of -$18339000.0. The EBITDA in the recently reported quarter was -$20297000.0 and diluted EPS was $nan.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SCLX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.